Synthetic Blood International, Inc. (SYBD.OB) Announced U.S. Department of Defense Awards $1.9 Million Grant
Synthetic announced yesterday that The United States Department of Defense approved the award of a $1.9 million grant to M. Ross Bullock, B.D., and Ph.D., of the University of Miami Miller School of Medicine, Department of Neurosurgery and principal investigator for the Company’s planned Phase llb clinical trial with Oxycyte™ for the treatment of traumatic brain injury. Oxycyte is the Synthetic Blood International’s perfluorocarbon therapeutic oxygen carrier and blood substitute. Dr. Bullock, C0-Chairman of the Company’s Scientific Advisory Board noted, “With this grant, we will be able to double our planned enrollment in the Phase llb trial to 200 TBI…